This $1,136,506 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports Vanderbilt University Medical Center's (VUMC) research on the role of integrin beta1 in clear cell renal cell carcinoma metastasis and growth. The award, with a period of performance from September 1, 2024 to August 31, 2028, enables VUMC to conduct innovative biomedical research aimed at advancing medical knowledge and improving patient care in this critical area. As a leading recipient of federal grants and contracts, VUMC leverages its clinical expertise and extensive research capabilities to deliver high-impact scientific studies through programs like this one sponsored by the Department of Defense.
Generated 2/25/25, 4:36 AM